<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68936">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02066740</url>
  </required_header>
  <id_info>
    <org_study_id>CP1007</org_study_id>
    <nct_id>NCT02066740</nct_id>
  </id_info>
  <brief_title>EverFlex™ Self-expanding Peripheral Stent With Entrust™ Delivery System Clinical Study</brief_title>
  <official_title>EverFlex™ Self-expanding Peripheral Stent With Entrust™ Delivery System Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Covidien</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Covidien</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect acute confirmatory data to evaluate technical
      success and acute safety of the EverFlex™ Self-expanding Peripheral Stent with Entrust™
      Delivery System.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Absence of stent elongation</measure>
    <time_frame>Intra operative</time_frame>
    <safety_issue>No</safety_issue>
    <description>Absence of stent elongation is achieved when the implanted stent length does not exceed the allowed stent length</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Successful stent deployment</measure>
    <time_frame>Procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Successful stent deployment to be assessed based on stent delivery, lesion coverage and accuracy of deployment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Peripheral Arterial Diseases</condition>
  <arm_group>
    <arm_group_label>EverFlex™ Stent with Entrust™ Delivery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EverFlex™ Stent with Entrust™ Delivery System</intervention_name>
    <arm_group_label>EverFlex™ Stent with Entrust™ Delivery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has stenotic, restenotic (from PTA or adjunct therapy, not including stents or stent
             grafts),

          -  or occluded lesion(s) located in the superficial femoral artery (SFA) and/or proximal
             popliteal artery (PPA) suitable for primary stenting.

        Exclusion Criteria:

          -  Has undergone previous implantation of stent(s) or stent graft(s) in the target
             vessel.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl M Wahlgren, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Covidien</last_name>
    <phone>763-398-7000</phone>
    <email>ENTRUST@Covidien.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum Weiden</name>
      <address>
        <city>Weiden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Christian Paetzel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 27, 2014</lastchanged_date>
  <firstreceived_date>February 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Superficial Femoral Artery</keyword>
  <keyword>Proximal Popliteal Artery</keyword>
  <keyword>Everflex</keyword>
  <keyword>Entrust</keyword>
  <keyword>stent</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
